Identification of differentially expressed proteins in triple-negative breast carcinomas using DIGE and mass spectrometry

Journal of Proteome Research

Volumn 8, Issue 7, 2009, Pages 3430-3438

  Schulz, Daniela M ^a   Böllner, Claudia ^a   Thomas, Gerry ^b   Atkinson, Mike ^a,c   Esposito, Irene ^a,d   Höfler, Heinz ^a,d   Aubele, Michaela ^a,d  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b HAMMERSMITH HOSPITAL   (United Kingdom)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

2D DIGE; Breast cancer; MALDI TOF TOFMS; Proteomics; Triple negative

Indexed keywords

BETA ACTIN; CYTOKERATIN 14; CYTOKERATIN 17; CYTOKERATIN 19; CYTOKERATIN 7; CYTOKERATIN 8; CYTOKERATIN 9; DELTA GLOBIN; DEOXYHEMOGLOBIN; ELECTRON TRANSFERRING FLAVOPROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FIBRONECTIN; FRUCTOSE BISPHOSPHATE ALDOLASE; FRUCTOSE BISPHOSPHATE ALDOLASE ISOENZYME; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; GLYCOLYTIC ENZYME; HEMOGLOBIN BETA CHAIN; IDITOL DEHYDROGENASE; LACTOFERRIN; LIPOCORTIN 2; MALEATE DEHYDROGENASE 2; NME1 NME2 PROTEIN; NUCLEOSIDE DIPHOSPHATE KINASE; PEROXIREDOXIN 1; PHOSPHOGLYCERATE KINASE; TRANSKETOLASE; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIMENTIN;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS; TWO DIMENSIONAL GEL ELECTROPHORESIS; WESTERN BLOTTING;

BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION PROFILING; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MASS SPECTROMETRY; PROTEINS; PROTEOME; PROTEOMICS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TUMOR MARKERS, BIOLOGICAL;

EID: 67650388533     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr900071h     Document Type: Article

References (51)

1. Lund, M. J.; Butler, E. N.; Bumpers, H. L.; Okoli, J. High prevalence of triple-negative tumors in an urban cancer center. Cancer 2008, 113, 608-615.
2. Bauer, K. R.; Brown, M.; Cress, R. D.; Parise, C. A.; Caggiano, V. Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109, 1721-1728.
3. Haffty, B. G.; Kim, J. H.; Yang, Q.; Higgins, S. A. Concurrent chemoradiation in the conservative management of breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 2006, 66, 1306-1312.
4. Perou, C. M.; Sorlie, T.; Eisen, M. B.; van de Rijn, M. Molecular portraits of human breast tumours. Nature 2000, 406, 747-752.
5. Sorlie, T.; Perou, C. M.; Tibshirani, R.; Aas, T. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98, 10869-10874.
6. Cleator, S.; Heller, W.; Coombes, R. C. Triple-negative breast cancer: therapeutic options. Lancet Oncol. 2007, 8, 235-244.
7. Altundag, K.; Harputluoglu, H.; Aksoy, S.; Gullu, I. H. Potential chemotherapy options in the triple negative subtype of breast cancer. J. Clin. Oncol. 2007, 25, 1294-1295, author reply 1295-1296.
8. Rakha, E. A.; El-Sayed, M. E.; Green, A. R.; Lee, A. H. Prognostic markers in triple-negative breast cancer. Cancer 2007, 109, 25-32.
9. Carey, C. M.; Kirk, J. L.; Ojha, S.; Kostrzynska, M. Current and future uses of real-time polymerase chain reaction and microarrays in the study of intestinal microbiota, and probiotic use and effectiveness. Can. J. Microbiol. 2007, 53, 537-550.
10. Reis-Filho, J. S.; Tutt, A. N. Triple negative tumours: a critical review. Histopathology 2008, 52, 108-118.
11. Smith, L.; Lind, M. J.; Welham, K. J.; Cawkwell, L. Cancer proteomics and its application to discovery of therapy response markers in human cancer. Cancer 2006, 107, 232-241.
12. Alban, A.; David, S. O.; Bjorkesten, L.; Andersson, C. A novel experimental design for comparative two-dimensional gel analysis: two-dimensional difference gel electrophoresis incorporating a pooled internal standard. Proteomics 2003, 3, 36-44.
13. Quintanilla-Martinez, L.; Davies-Hill, T.; Fend, F.; Calzada-Wack, J.; et al. Sequestration of p27Kip1 protein by cyclin D1 in typical and blastic variants of mantle cell lymphoma (MCL): implications for pathogenesis. Blood 2003, 101, 3181-3187.
14. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 1976, 72, 248-254.
15. O'Connell, K. L.; Stults, J. T. Identification of mouse liver proteins on two-dimensional electrophoresis gels by matrix-assisted laser desorption/ionization mass spectrometry of in situ enzymatic digests. Electrophoresis 1997, 18, 349-359.
16. Kijima, T.; Maulik, G.; Ma, P. C.; Madhiwala, P. Fibronectin enhances viability and alters cytoskeletal functions (with effects on the phosphatidylinositol 3-kinase pathway) in small cell lung cancer. J. Cell. Mol. Med. 2003, 7, 157-164.
17. Damiens, E.; El Yazidi, I.; Mazurier, J.; Duthille, I. Lactoferrin inhibits G1 cyclin-dependent kinases during growth arrest of human breast carcinoma cells. J. Cell. Biochem. 1999, 74, 486-498.
18. Dhennin-Duthille, I.; Masson, M.; Damiens, E.; Fillebeen, C. Lactoferrin upregulates the expression of CD4 antigen through the stimulation of the mitogen-activated protein kinase in the human lymphoblastic T Jurkat cell line. J. Cell. Biochem. 2000, 79, 583-593.
19. Grey, A.; Banovic, T.; Zhu, Q.; Watson, M. The low-density lipoprotein receptor-related protein 1 is a mitogenic receptor for lactoferrin in osteoblastic cells. Mol. Endocrinol. 2004, 18, 2268-2278.
20. Haversen, L.; Ohlsson, B. G.; Hahn-Zoric, M.; Hanson, L. A.; Mattsby-Baltzer, I. Lactoferrin down-regulates the LPS-induced cytokine production in monocytic cells via NF-kappa B. Cell. Immunol. 2002, 220, 83-95.
21. Oh, S. M.; Pyo, C. W.; Kim, Y.; Choi, S. Y. Neutrophil lactoferrin upregulates the human p53 gene through induction of NF-kappaB activation cascade. Oncogene 2004, 23, 8282-8291.
22. Brouillard, F.; Fritsch, J.; Edelman, A.; Ollero, M. Contribution of proteomics to the study of the role of cytokeratins in disease and physiopathology. Proteomics: Clin. Appl. 2008, 2, 264-285.
23. Zhang, D.; Tai, L. K.; Wong, L. L.; Chiu, L. L. Proteomic study reveals that proteins involved in metabolic and detoxification pathways are highly expressed in HER-2/neu-positive breast cancer. Mol. Cell. Proteomics 2005, 4, 1686-1696.
24. He, T.; Stepulak, A.; Holmstrom, T. H.; Omary, M. B.; Eriksson, J. E. The intermediate filament protein keratin 8 is a novel cytoplasmic substrate for c-Jun N-terminal kinase. J. Biol. Chem. 2002, 277, 10767-10774.
25. Rakha, E. A.; Reis-Filho, J. S.; Ellis, I. O. Basal-like breast cancer: a critical review. J. Clin. Oncol. 2008, 26, 2568-2581.
26. Laakso, M.; Loman, N.; Borg, A.; Isola, J. Cytokeratin 5/14-positive breast cancer: true basal phenotype confined to BRCA1 tumors. Mod. Pathol. 2005, 18, 1321-1328.
27. Sommers, C. L.; Walker-Jones, D.; Heckford, S. E.; Worland, P. Vimentin rather than keratin expression in some hormone-independent breast cancer cell lines and in oncogene-transformed mammary epithelial cells. Cancer Res. 1989, 49, 4258-4263.
28. Korsching, E.; Packeisen, J.; Liedtke, C.; Hungermann, D. The origin of vimentin expression in invasive breast cancer: epithelial-mesenchymal transition, myoepithelial histogenesis or histogenesis from progenitor cells with bilinear differentiation potential. J. Pathol. 2005, 206, 451-457.
29. Lin, C. S.; Lau, A.; Yeh, C. C.; Chang, C. H.; Lue, T. F. Upregulation of L-plastin gene by testosterone in breast and prostate cancer cells: identification of three cooperative androgen receptor-binding sequences. DNA Cell Biol. 2000, 19, 1-7.
30. Fenhalls, G.; Geyp, M.; Dent, D. M.; Parker, M. I. Breast tumour cell-induced down-regulation of type I collagen mRNA in fibroblasts. Br. J. Cancer 1999, 81, 1142-1149.
31. Young, C. D.; Anderson, S. M. Sugar and fat - that's where it's at: metabolic changes in tumors. Breast Cancer Res. 2008, 10, 202.
32. van den Bemd, G. J.; Krijgsveld, J.; Luider, T. M.; van Rijswijk, A. L. Mass spectrometric identification of human prostate cancer-derived proteins in serum of xenograft-bearing mice. Mol. Cell. Proteomics 2006, 5, 1830-1839.
33. Popanda, O.; Fox, G.; Thielmann, H. W. Modulation of DNA polymerases alpha, delta and epsilon by lactate dehydrogenase and 3-phosphoglycerate kinase. Biochim. Biophys. Acta 1998, 1397, 102-117.
34. Kabbage, M.; Chahed, K.; Hamrita, B.; Guillier, C. L. Protein alterations in infiltrating ductal carcinomas of the breast as detected by nonequilibrium pH gradient electrophoresis and mass spectrometry. J. Biomed. Biotechnol. 2008, 2008, 564127.
35. Vishwanatha, J. K.; Salazar, E.; Gopalakrishnan, V. K. Absence of annexin I expression in B-cell non-Hodgkin's lymphomas and cell lines. BMC Cancer 2004, 4, 8.
36. Alldridge, L. C.; Harris, H. J.; Plevin, R.; Hannon, R.; Bryant, C. E. The annexin protein lipocortin 1 regulates the MAPK/ERK pathway. J. Biol. Chem. 1999, 274, 37620-37628.
37. Kreunin, P.; Yoo, C.; Urquidi, V.; Lubman, D. M.; Goodison, S. Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics 2007, 7, 299-312.
38. Ahn, S. H.; Sawada, H.; Ro, J. Y.; Nicolson, G. L. Differential expression of annexin I in human mammary ductal epithelial cells in normal and benign and malignant breast tissues. Clin. Exp. Metastasis 1997, 15, 151-156.
39. Shen, D.; Nooraie, F.; Elshimali, Y.; Lonsberry, V. Decreased expression of annexin A1 is correlated with breast cancer development and progression as determined by a tissue microarray analysis. Hum. Pathol. 2006, 37, 1583-1591.
40. Shen, D.; Chang, H. R.; Chen, Z.; He, J. Loss of annexin A1 expression in human breast cancer detected by multiple high-throughput analyses. Biochem. Biophys. Res. Commun. 2005, 326, 218-227.
41. Cao, Y.; Li, Y.; Edelweiss, M.; Arun, B. Loss of annexin A1 expression in breast cancer progression. Appl. Immunohistochem. Mol. Morphol. 2008, 16, 530-534.
42. Sharma, M. R.; Koltowski, L.; Ownbey, R. T.; Tuszynski, G. P.; Sharma, M. C. Angiogenesis-associated protein annexin II in breast cancer: selective expression in invasive breast cancer and contribution to tumor invasion and progression. Exp. Mol. Pathol. 2006, 81, 146-156.
43. Chuthapisith, S.; Layfield, R.; Kerr, I. D.; Hughes, C.; Eremin, O. Proteomic profiling of MCF-7 breast cancer cells with chemoresistance to different types of anti-cancer drugs. Int. J. Oncol. 2007, 30, 1545-1551.
44. Davidson, L. A.; Lonnerdal, B. Fe-saturation and proteolysis of human lactoferrin: effect on brush-border receptor-mediated uptake of Fe and Mn. Am. J. Physiol. 1989, 257, G930-934.
45. Oh, S. M.; Hahm, D. H.; Kim, I. H.; Choi, S. Y. Human neutrophil lactoferrin trans-activates the matrix metalloproteinase 1 gene through stress-activated MAPK signaling modules. J. Biol. Chem. 2001, 276, 42575-42579.
46. Karihtala, P.; Mantyniemi, A.; Kang, S. W.; Kinnula, V. L.; Soini, Y. Peroxiredoxins in breast carcinoma. Clin. Cancer Res. 2003, 9, 3418-3424.
47. Dhalla, N. S.; Temsah, R. M.; Netticadan, T. Role of oxidative stress in cardiovascular diseases. J. Hypertens. 2000, 18, 655-673.
48. Ambrosone, C. B. Oxidants and antioxidants in breast cancer. Antioxid. Redox Signaling 2000, 2, 903-917.
49. Klaunig, J. E.; Xu, Y.; Isenberg, J. S.; Bachowski, S. The role of oxidative stress in chemical carcinogenesis. Environ. Health Perspect. 1998, 106 (1), 289-295.
50. Florenes, V. A.; Aamdal, S.; Myklebost, O.; Maelandsmo, G. M. Levels of nm23 messenger RNA in metastatic malignant melanomas: inverse correlation to disease progression. Cancer Res. 1992, 52, 6088-6091.
51. Youn, B.; Kim, H. D.; Kim, J. Nm23-H1/nucleoside diphosphate kinase as a key molecule in breast tumor angiogenesis. Expert Opin. Ther. Targets 2008, 12, 1419-1430.